Wegovy 0.5mg in the dose schedule: what to expect at this stage

Wegovy 0.5mg is a titration step, not the maintenance dose — the licensed maintenance dose for weight management is 2.4mg (or 7.2mg where the higher-dose pen is prescribed).
The 0.25mg starter and 0.5mg second step are designed to reduce early side effects, primarily nausea, before the dose increases further.
Each dose level is typically held for around four weeks before the prescriber considers moving up.
Semaglutide is a GLP-1 receptor agonist: it slows stomach emptying and acts on appetite centres in the brain, reducing hunger and calorie intake over time.

Wegovy 0.5mg is the second step in the semaglutide titration ladder, taken once weekly after four weeks on the 0.25mg starting dose. It is not a maintenance dose — it is part of a structured escalation that lets your body adjust gradually before reaching the doses where most clinical weight-loss effect occurs. Like all Wegovy doses, it is a prescription-only medicine; a prescriber assesses whether it is right for you before any treatment begins.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How the 0.5mg dose fits into Wegovy treatment, and what comes next

Step 1: why the dose starts low and climbs slowly

Wegovy's titration schedule exists for a practical reason. Semaglutide slows gastric emptying and acts on hunger signals in the brain, and those effects can produce nausea, indigestion or loose stools, particularly in the early weeks. Starting at 0.25mg for the first month gives the body time to settle before the dose increases to 0.5mg for weeks five through eight.

At 0.5mg, most people notice the gastrointestinal side effects beginning to ease from where they were at the start. Some find appetite suppression becomes more noticeable than it was at 0.25mg, though the dose is still well below the therapeutic levels studied for weight management. If you want a closer look at what this stage involves, our dedicated page on the Wegovy 0.5mg pen covers the specifics in detail. The NHS medicines page for semaglutide sets out the full titration schedule and what to expect at each stage, worth reading before your first pen arrives.

The schedule after 0.5mg continues upward: 1.0mg, then 1.7mg, then 2.4mg, with each step roughly four weeks apart, guided by your prescriber. Our guide to the 1mg dose covers what changes at that next stage.

Step 2: what the trial evidence actually shows, and when it applies

It is worth being clear about what the clinical evidence covers. The STEP 1 trial, published in the New England Journal of Medicine, studied semaglutide 2.4mg over 68 weeks and reported an average weight reduction of around 15% in adults without type 2 diabetes. That figure applies to the full maintenance dose held for more than a year, not to 0.5mg, which most people pass through in a single four-week period.

This matters because some people expect visible weight loss within the first eight weeks. The titration phase (0.25mg and 0.5mg) is largely about tolerability and adjustment. Significant weight loss tends to build once maintenance doses are reached and sustained. Patience at this stage is not a sign that the medicine is not working.

If you are curious about how Wegovy's results compare more broadly, our Wegovy overview page summarises what the evidence says across the full course of treatment.

Step 3: side effects that are most common at this dose

The side effects most frequently reported with semaglutide are gastrointestinal: nausea, constipation, diarrhoea, burping, and indigestion. These are generally most pronounced at the start of treatment and after each dose increase. At 0.5mg, some people find they experience a mild recurrence of the nausea they had at 0.25mg; for others, the step up passes without much notice. You can get a clearer sense of how this dose lands in practice by reading what other patients have said about their experience at 0.5mg.

Staying hydrated, eating smaller portions and avoiding high-fat meals can help. If side effects feel unmanageable, that is a conversation to have with your prescriber, not a reason to stop without guidance. Serious reactions are uncommon, but the MHRA advises seeking urgent medical attention for severe, persistent stomach pain that spreads to the back, which can be a sign of pancreatitis. You can report any suspected side effect through the Yellow Card scheme.

Wegovy is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for anyone under 18. Your prescriber will discuss your full medical history as part of the assessment.

Step 4: accessing Wegovy and what clinical assessment involves

Wegovy is a prescription-only medicine. The only legal route to it in the UK is through a prescriber who has assessed your suitability, there is no way around that step, and any seller offering it without one should be treated as a red flag. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online; genuine supply comes through the licensed UK pharmacy chain.

On the NHS, Wegovy is available through specialist weight management services under NICE's appraisal TA875, which sets specific eligibility criteria and a two-year treatment limit within those services. Waiting times vary considerably by area. If you are exploring a private route, it helps to understand what a legitimate service looks like: a GPhC-registered pharmacy, a named prescriber reviewing your consultation, and identity and weight checks before treatment is approved.

If payday falls on a Friday and you are hoping to order over the weekend, it is worth knowing that same-day dispatch applies to weekday orders placed before 12pm, Monday tends to be a popular restart point for people who have been thinking it over.

For a fuller picture of what the assessment and ordering process looks like, our guide to getting Wegovy online covers the steps in plain detail. You can also read about how our clinical team approaches prescribing decisions on the clinical team page. If treatment costs are part of your thinking, our weight-loss treatment overview puts private pricing in context. If you are already thinking ahead to later stages, our guide to the Wegovy 2mg dose explains what that part of the journey looks like. When you are ready to take the next step, you can start a free consultation and a GPhC-registered prescriber will review your answers the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions